Akebia Therapeutics is a fully integrated biopharmaceutical company based in Copley, OH, dedicated to advancing new hope for people with kidney disease. Their team works tirelessly to address complications of kidney disease and deliver unique products to patients and families affected by this serious and life-altering illness.
With a commercially available medicine and a late-stage oral hypoxia inducible factor prolyl hydroxylase inhibitor, Akebia is a trusted leader in the renal community, committed to innovation and making a difference by challenging the status quo in the field of kidney disease research and development.
Generated from the website